TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

TransMedics Group (NASDAQ:TMDX) had its target price decreased by equities researchers at TD Cowen from $190.00 to $120.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s price objective indicates a potential upside of 64.68% from the stock’s current price.

Several other research firms have also recently issued reports on TMDX. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Needham & Company LLC decreased their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday. Piper Sandler decreased their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Stifel Nicolaus decreased their price objective on shares of TransMedics Group from $130.00 to $85.00 and set a “hold” rating for the company in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.40.

TransMedics Group Stock Down 23.2%

Shares of NASDAQ:TMDX traded down $22.06 during trading on Wednesday, hitting $72.87. The company’s stock had a trading volume of 6,872,613 shares, compared to its average volume of 962,752. The business has a 50 day moving average price of $116.57 and a two-hundred day moving average price of $125.96. The company has a market capitalization of $2.52 billion, a PE ratio of 14.87 and a beta of 2.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. TransMedics Group has a fifty-two week low of $70.00 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The business had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.48 million. TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.The business’s revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.70 EPS. As a group, research analysts expect that TransMedics Group will post 2.48 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, CFO Gerardo Hernandez sold 7,236 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the sale, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at $2,162,367.69. The trade was a 33.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 864 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $120,199.68. Following the completion of the sale, the insider directly owned 13,091 shares of the company’s stock, valued at approximately $1,821,219.92. This trade represents a 6.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,205 shares of company stock valued at $2,353,002 over the last quarter. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kensington Investment Counsel LLC purchased a new stake in TransMedics Group in the third quarter valued at $1,926,000. Nordea Investment Management AB purchased a new stake in shares of TransMedics Group in the third quarter valued at about $4,070,000. Peregrine Capital Management LLC raised its holdings in shares of TransMedics Group by 16.5% in the third quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock valued at $7,675,000 after buying an additional 9,676 shares during the last quarter. Fieldview Capital Management LLC purchased a new stake in shares of TransMedics Group in the third quarter valued at about $1,716,000. Finally, Citigroup Inc. raised its holdings in shares of TransMedics Group by 29.3% in the third quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock valued at $8,615,000 after buying an additional 17,414 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Needham cut its price target but remains constructive — Needham lowered its target from $174 to $142 and kept a “buy” rating, implying substantial upside if fundamentals re-accelerate. Needham PT cut
• Positive Sentiment: Piper Sandler also kept an overweight stance despite cutting its target to $120, signaling that some brokers still see medium-term upside. Piper Sandler PT change
• Neutral Sentiment: Top-line growth remains intact — Q1 revenue rose ~21% year-over-year to $173.93M driven by OCS demand and logistics growth, indicating continued commercial traction even as profitability slipped. Zacks revenue coverage
• Negative Sentiment: Material EPS and margin miss — TMDX reported $0.30 EPS vs. consensus ~$0.62 and noted margin pressure; markets penalize the earnings and the deterioration in profitability. Earnings release
• Negative Sentiment: Analyst tone turned more cautious — Oppenheimer downgraded TMDX from “outperform” to “market perform” and Stifel cut its PT from $130 to $85 and moved to “hold”, increasing selling pressure. Oppenheimer downgrade Stifel PT cut
• Negative Sentiment: FY26 revenue guidance range ($727M–$757M) sits around Wall Street’s view and may be read as cautious vs. expectations, leaving less near-term upside and amplifying focus on margins and execution. PR Newswire guidance

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.